A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence

Investigator:  Bill G Schmidt, MD

Status: Recruiting

Phase: 3

Sponsor: Polynoma LLC

Contact: Jennifer Montgomery, 541-706-6590 or jmontgomery@bmctotalcare.com

Location: Bend, Oregon (Central Oregon)


The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients who have undergone surgery.

Inclusion Criteria:

  • Histologically confirmed Stage IIb, IIc, III melanoma
  • Surgical resection within 90 days of first dosing
  • Persons with positive sentinel nodes must have a complete lymphadenectomy
  • ECOG performance status 0 or 1

Exclusion Criteria:

  • Any prior melanoma treatment other than surgery or regional irradiation
  • Diagnosis of non-cutaneous melanoma or melanoma with unknown primary origin
  • Use of biologic response modifiers within 60 days of first dosing
  • Subjects with history of other malignancy within past 5 years (with exceptions)

See this trial at ClinicalTrials.gov

For general inquiries, please contact the BMC Research Department at research@bmctotalcare.com or 877-692-8338.

Back to Clinical Research


Post Comment